Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant

Radiotherapy and Oncology

Volumn 64, Issue 1, 2002, Pages 37-40

  MacRae, Rob ^a   Shyr, Yu ^a   Johnson, David ^a   Choy, Hak ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; Hemoglobin; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; HEMOGLOBIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; BLOOD; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0036629604     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00151-2     Document Type: Article

References (18)

1. Bristow R.G., Hill R.P. Molecular and cellular basis of radiotherapy. Tannock I.F., Hill R.P., The basic science of oncology. 3rd ed. 1998;295-321 McGraw-Hill, Montreal.
2. Choy H., Safran H., Akerley W., Graziano S.L., Bogart J.A., Cole B.F. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 4:(8):1998;1931-1936.
3. Choy H., Akerley W., Safran H., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 16:(10):1998;3316-3322.
4. Choy H., Devore R.F. 3rd, Hande K.R., et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys. 47:(4):2000;931-937.
5. Choy H., DeVore R., Akerley W., et al. Sequential phase II studies of paclitaxel +/- carboplatin and radiation therapy (+/- hyperfractionation) for locally advanced non-small cell lung cancer (NSCLC): multiinstitutional trials (Abstract 1951). Proc Am Soc Clin Oncol. 19:2000;499a.
6. Curran W.J., Scott C., Langer C., et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 (Abstract 303). Lung Cancer. 29:(S1):2000;93.
7. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 36:2000;1649-1660.
8. Girinski T., Pejovic-Lenfant M.H., Bourhis J., et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys. 16:1989;37-42.
9. Glaser C., Millesi W., Kornek G., et al. Impact of hemoglobin level and the use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 50:(3):2001;705-715.
10. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
11. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 86:(8):1999;1528-1536.
12. Lee J.S., Komaki R., Touroutoglou N., et al. Erythropoeitin prevents anemia during concurrent chemo-radiation for locally advanced inoperable non-small cell lung cancer (Abstract 1780). Proc Am Soc Clin Oncol. 17:1998;463a.
13. Overgarrd J., Hansen H.S., Jorgenson K., Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma - an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys. 121:(4):1986;515-521.
14. Sasai K., Ono K., Hiraoka M., et al. The effect of arterial oxygen content on the results of radiation therapy for epidermoid bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 16:1989;1477-1481.
15. Tarnawaski R., Skladowski K., Maciejewski B. Prognostic value of hemoglobin concentration for cancer of the suprglottic larynx. Int J Radiat Oncol Biol Phys. 38:(5):1997;1007-1011.
16. Vijayakumar S., Roach M., Wrar W., et al. Effect of subcutaneous recombinant human erythropoeitin in cancer patients receiving radiotherapy: preliminary results of a randomized, open labeled, phase II trial. Int J Radiat Oncol Biol Phys. 26:1993;721-729.
17. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 48:(5):2000;1475-1482.
18. Wigren T., Oksanen H., Kellokumpu-Lehtinen P. A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol. 123:1997;259-266.